ArcticZymes Technologies (AZT) Pareto Securities 15th Healthcare Conference Presentation summary

Business overview and market position

• Develops novel enzymes for biomanufacturing and molecular research/diagnostics, supported by numerous publications.

• Holds a strong reputation in Molecular Tools and Biomanufacturing, with a Net Promoter Score of 84.

• Serves over 300 B2B customers globally, including life science tools, CDMO, pharma, and biotech companies.

• Direct sales channels in the US (45%), Europe (50%), and Rest of World (5%).

• Employs 53 staff, headquartered in Tromsø, Norway, with a world-class R&D and manufacturing team.

Product portfolio and innovation

• Offers a broad enzyme portfolio for biomanufacturing, molecular workflows, and diagnostics.

• Provides custom and OEM solutions, including nucleases, polymerases, ligases, and reverse transcriptases.

• Features a leading nuclease portfolio, optimized for various bioprocessing conditions (low/high salt).

• Plans to launch two new GMP-grade nucleases and an ELISA kit within 12 months.

• Focuses on continuous innovation, including RNA enzymes and NextGen AI SAN.

Financial performance and growth strategy

• Achieves margins above 90% on all products, with 2023 sales of 119 MNOK and ongoing profitability.

• Maintains a strong balance sheet with no debt and 240 MNOK in cash reserves.

• Recurring revenue streams and a sticky business model.

• Listed on the Norwegian Stock Exchange with a 30-year track record.

• Strategic priorities include market-driven transformation, commercialization excellence, and M&A opportunities.